The FDA has approved RediTrex (methotrexate injection; Cumberland) for the management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis, who are intolerant of or had an inadequate response to first-line therapy.
Researchers evaluated the efficacy and safety of abatacept in pediatric patients with polyarticular-course juvenile idiopathic arthritis.
Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are rare diseases that are generally specific to the lungs, kidneys and upper airways.
Researchers highlighted the use of pharmacologic stress cardiovascular magnetic resonance (PSCMR) in specific pediatric cohorts with congenital and acquired heart disease. They also presented 2 cases of patients with Kawasaki disease, in which PSCMR helped in decision making.
Researchers highlighted the clinical factors that reduce the sensitivity of inflammatory markers in the diagnosis of pediatric osteomyelitis.
Researchers evaluated Canadian claims level data to assess the utilization of methotrexate and prednisone in patients with JIA who initiated etanercept therapy.
Researchers validated the 2017 weighted, 1997 ACR, and 2012 SLICC criteria and compared their sensitivities and specificities in patients with pediatric systemic lupus erythematosus.
Researchers evaluated the efficacy of bisphosphonate risedronate vs alfacalcidol in steroid-induced osteopenia in children.
The study assessed the implications of genetic advances in juvenile idiopathic arthritis; the results of the research may be useful in the treatment of arthritis in children.
The study evaluated IL-18 levels in systemic juvenile idiopathic arthritis by assessing disease activity, history of macrophage activation syndrome, and other disease biomarkers.
